Semaglutide (Ozempic/Wegovy) changed the weight loss landscape. Now retatrutide — a triple-action injectable — is producing results that dwarf it in clinical trials. This head-to-head comparison breaks down everything Malaysian patients need to know: how the two drugs work, how much weight they help you lose, what they cost, and which one might be right for you.
Key Takeaways
- Semaglutide (Ozempic/Wegovy) is a single GLP-1 agonist producing ~15% weight loss — available now in Malaysia
- Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) producing up to 24.2% weight loss in Phase 2 trials — roughly 60% more than semaglutide
- The glucagon component in retatrutide increases resting metabolic rate and fat burning — semaglutide only reduces appetite
- Side effects are broadly similar (GI symptoms), though retatrutide shows a modest heart rate increase from the glucagon component
- Price projection: Semaglutide costs RM800–1,800/month in Malaysia; retatrutide is projected at RM2,500–4,500/month
- Availability: Semaglutide is available now. Retatrutide is estimated for Malaysia in 2029–2030
- Bottom line: If you need treatment today, semaglutide is proven and accessible. Retatrutide will likely be the superior drug — but it's years away
Medical Disclaimer: Retatrutide is an investigational drug not yet approved by any regulatory authority worldwide. Semaglutide (Ozempic/Wegovy) is a prescription medication that should only be used under medical supervision. This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or switching any medication.
Single Agonist vs Triple Agonist: How They Work
The fundamental difference between semaglutide and retatrutide comes down to how many metabolic pathways each drug activates.
Semaglutide: One Receptor, One Mechanism
Semaglutide — sold as Ozempic (for diabetes) and Wegovy (for weight management) — is a GLP-1 receptor agonist. It mimics the natural gut hormone GLP-1, which:
- Suppresses appetite by acting on hunger centres in the brain
- Slows gastric emptying — food stays in your stomach longer, so you feel full sooner
- Improves insulin secretion in response to meals
- Reduces glucagon release (lowering blood sugar)
This single mechanism is remarkably effective. In the STEP trials, semaglutide 2.4 mg (Wegovy) produced an average of ~15–17% body weight loss over 68 weeks — a result that reshaped the entire obesity treatment field.
But semaglutide's approach is essentially one-dimensional: it works primarily by making you eat less.
Retatrutide: Three Receptors, Three Mechanisms
Retatrutide (LY3437943, Eli Lilly) is a triple hormone receptor agonist — the first drug ever to simultaneously target GLP-1, GIP, and glucagon receptors. Here's what each adds:
- GLP-1 receptor — The same appetite-suppressing, insulin-improving mechanism as semaglutide
- GIP (glucose-dependent insulinotropic polypeptide) receptor — Enhances insulin sensitivity, improves fat metabolism, and amplifies GLP-1's effects. This is the same second mechanism used in Mounjaro (tirzepatide)
- Glucagon receptor — The truly novel component. Glucagon activation increases your basal metabolic rate (you burn more calories at rest), promotes lipolysis (fat breakdown), and dramatically reduces liver fat
The critical insight: semaglutide reduces energy in (you eat less). Retatrutide reduces energy in and increases energy out (you eat less AND burn more). This dual approach is why the weight loss gap between the two drugs is so large.
| Feature | Semaglutide (Ozempic/Wegovy) | Retatrutide |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Drug class | GLP-1 receptor agonist | GLP-1/GIP/glucagon triple agonist |
| Receptors targeted | 1 | 3 |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Primary weight loss mechanism | Appetite suppression | Appetite suppression + increased energy expenditure |
| Regulatory status | FDA/NPRA approved | Phase 3 trials (not approved) |
Weight Loss Comparison: 15% vs 24%
The numbers tell a striking story. While these come from separate trials (not a direct head-to-head study), the difference is large enough to be clinically meaningful.
Semaglutide Weight Loss Data
From the STEP 1 trial (Wilding et al., NEJM 2021) — semaglutide 2.4 mg in adults with obesity over 68 weeks:
- Mean weight loss: 14.9%
- 32% of participants achieved ≥20% weight loss
- 86% achieved ≥5% weight loss
For a 100 kg person, that's approximately 15 kg lost.
Retatrutide Weight Loss Data
From the Phase 2 trial (Jastreboff et al., NEJM 2023) — retatrutide 12 mg in adults with obesity over 48 weeks:
- Mean weight loss: 24.2%
- 93% of participants achieved ≥15% weight loss
- The weight loss curve had not yet plateaued at 48 weeks
For a 100 kg person, that's approximately 24 kg lost — and likely more with continued treatment. For detailed efficacy data, see our retatrutide results breakdown.
What the Gap Means in Practice
An additional ~9 percentage points of weight loss is clinically transformative. Consider a Malaysian woman weighing 90 kg:
- On semaglutide: She might lose ~13.5 kg, reaching 76.5 kg
- On retatrutide: She might lose ~21.8 kg, reaching 68.2 kg
That 8 kg difference can mean the difference between still being classified as obese versus reaching a healthy BMI range. It can also unlock additional metabolic improvements — better blood pressure, better cholesterol, potential remission of type 2 diabetes, and resolution of fatty liver disease.
| Metric | Semaglutide 2.4 mg | Retatrutide 12 mg |
|---|---|---|
| Trial phase | Phase 3 (approved) | Phase 2 (investigational) |
| Trial duration | 68 weeks | 48 weeks |
| Mean weight loss | 14.9% | 24.2% |
| ≥10% weight loss | 69% | ~93% |
| ≥20% weight loss | 32% | ~75% |
| Weight loss plateau? | Yes, by ~60 weeks | Not yet at 48 weeks |
Important caveat: Retatrutide's data is from a smaller Phase 2 trial. Phase 3 results (from the ongoing TRIUMPH programme) may show slightly more modest numbers — likely in the 20–25% range. Even the conservative end would substantially outperform semaglutide. For a comparison with Eli Lilly's other drug, see retatrutide vs tirzepatide.
Metabolic Benefits Beyond Weight Loss
Both drugs deliver benefits that extend well beyond the number on the scale — but retatrutide's triple mechanism provides advantages that semaglutide simply cannot match.
Blood Sugar and Type 2 Diabetes
Semaglutide is an excellent diabetes drug (Ozempic is primarily indicated for type 2 diabetes). Retatrutide's three-receptor approach may improve glucose control even further — Phase 2 data showed significant HbA1c reductions comparable to or exceeding semaglutide.
Liver Fat (MASH/NAFLD)
This is where retatrutide truly separates itself. The glucagon receptor activation drives dramatic liver fat reduction. In Phase 2, retatrutide reduced liver fat by up to ~80% in participants with fatty liver disease. Semaglutide also reduces liver fat, but the effect is more modest (~40–50% in trials). Eli Lilly is running a dedicated Phase 3 trial (TRIUMPH-4) for MASH — this could become a major indication.
This is especially relevant for Malaysia, where non-alcoholic fatty liver disease affects an estimated 25–30% of adults.
Cardiovascular Health
Semaglutide has a proven cardiovascular benefit — the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in people with obesity. This is a significant advantage for semaglutide today, as no cardiovascular outcomes data exists for retatrutide yet. The TRIUMPH-3 trial is investigating this, with results expected in 2028–2029.
Resting Metabolic Rate
A major concern with any weight loss is metabolic adaptation — your body burns fewer calories as you lose weight, making further loss harder and regain more likely. Semaglutide doesn't address this. Retatrutide's glucagon component may directly counteract metabolic adaptation by maintaining or increasing resting energy expenditure. If confirmed in Phase 3, this would be a significant advantage for long-term weight maintenance.
| Metabolic Benefit | Semaglutide | Retatrutide |
|---|---|---|
| Blood sugar control | Strong (proven) | Strong (Phase 2 data) |
| Liver fat reduction | Moderate (~40–50%) | Dramatic (~80%) |
| Cardiovascular outcomes | Proven (SELECT trial) | Under investigation (TRIUMPH-3) |
| Metabolic rate preservation | No direct effect | Likely (glucagon mechanism) |
| Sleep apnoea improvement | Shown in STEP 8 | Under investigation (TRIUMPH-5) |
Side Effect Comparison
Both drugs share a common GLP-1 backbone, so the core side effect profile is similar. The differences come from retatrutide's additional receptor targets.
Shared Side Effects (GLP-1 Related)
- Nausea — The most common side effect for both drugs, typically worst during dose escalation and improving over weeks
- Diarrhoea and constipation — Gastrointestinal effects are par for the course with any GLP-1 agonist
- Vomiting — More common at higher doses for both
- Decreased appetite — Often considered a therapeutic effect rather than a side effect
- Injection site reactions — Mild and infrequent for both
Semaglutide-Specific Concerns
- Pancreatitis risk: Rare but documented; applies to all GLP-1 agonists
- Gallbladder issues: Increased risk of gallstones with rapid weight loss
- Thyroid C-cell tumours: Black box warning based on rodent studies (not confirmed in humans)
Retatrutide-Specific Concerns
- Modest heart rate increase: The glucagon component slightly raises resting heart rate. Phase 2 data showed this was not clinically significant, but Phase 3 will provide clearer long-term data
- Slightly higher GI side effect rates: Diarrhoea was somewhat more common with retatrutide than with semaglutide in trials, likely due to the multi-receptor activation
- Long-term unknowns: As an unapproved drug, the long-term safety profile of the triple-agonist combination is not yet established
Overall, both drugs were well-tolerated in their respective trials. Discontinuation rates due to side effects were low for both — generally under 10%. The GI side effects are typically manageable with slow dose escalation and dietary adjustments.
Availability in Malaysia
Semaglutide: Available Now
Ozempic (semaglutide) is NPRA-approved and widely available across Malaysia. You can obtain it from:
- Endocrinologists and weight management specialists
- Private hospitals (Sunway Medical, Gleneagles, Pantai, Prince Court)
- Aesthetic and wellness clinics in KL, Penang, and JB
- Some general practitioners with appropriate training
Wegovy (higher-dose semaglutide for weight management) has also received NPRA registration, expanding options for patients whose primary goal is weight loss rather than diabetes management.
Retatrutide: 2029–2030 (Estimated)
Retatrutide is not approved anywhere in the world. The projected timeline for Malaysia:
- Late 2026–2027: Phase 3 TRIUMPH data readouts
- Late 2027–2028: FDA approval (US)
- 2028–2029: NPRA submission
- 2029–2030: NPRA approval and clinic availability
Eli Lilly's existing Malaysian infrastructure (from Mounjaro) could accelerate the launch. The NPRA has historically been efficient with drugs that already hold FDA/EMA approval — Mounjaro received NPRA registration within ~12–18 months of US approval.
Warning: Do not buy "retatrutide" from online sellers, grey-market sources, or compounding pharmacies. The drug is not commercially manufactured. Any product sold under this name is counterfeit or research-grade chemical not intended for human use.
Pricing Comparison in Malaysia (RM)
Cost is a major factor for Malaysian patients, especially since most private insurance plans do not cover weight loss medications.
| Drug | Monthly Cost (RM) | Annual Cost (RM) | Status |
|---|---|---|---|
| Ozempic (semaglutide 1 mg) | RM800–1,800 | RM9,600–21,600 | Available now |
| Wegovy (semaglutide 2.4 mg) | RM1,500–2,500 | RM18,000–30,000 | Available now |
| Mounjaro (tirzepatide) | RM1,088–3,000 | RM13,056–36,000 | Available now |
| Retatrutide (projected) | RM2,500–4,500 | RM30,000–54,000 | 2029–2030 |
Cost-Effectiveness Perspective
While retatrutide will cost more per month, the cost per kilogram lost may actually be competitive — or even favourable — compared to semaglutide:
- Semaglutide: ~RM1,300/month average ÷ ~1.1 kg/month ≈ RM1,180 per kg lost
- Retatrutide (projected): ~RM3,500/month ÷ ~2.0 kg/month ≈ RM1,750 per kg lost
When you factor in the additional metabolic benefits (liver fat reduction, potential metabolic rate preservation, possible reduction in downstream healthcare costs), retatrutide's value proposition may be stronger than the headline price suggests.
By 2029–2030, competition from multiple next-generation drugs (including oral options like orforglipron) could also moderate pricing across the entire category. For current costs, see our weight loss injection prices in Malaysia guide.
Which Should You Choose?
The honest answer depends on timing, goals, and individual circumstances.
Choose Semaglutide (Ozempic/Wegovy) If:
- You need treatment now. Semaglutide is available today in Malaysia — retatrutide is 3–4 years away
- You have type 2 diabetes. Ozempic is specifically indicated for diabetes and has extensive long-term safety data
- Cardiovascular protection matters. Semaglutide is the only obesity drug with proven MACE reduction (SELECT trial)
- Budget is a concern. Ozempic starts at ~RM800/month — significantly cheaper than projected retatrutide pricing
- You want a proven track record. Millions of patients worldwide have used semaglutide since 2017. The safety profile is well-characterised
- 10–17% weight loss meets your goals. For many patients, this level of weight loss is life-changing
Consider Waiting for Retatrutide If:
- You have significant fatty liver disease (MASH/NAFLD). Retatrutide's liver fat reduction is dramatically superior
- You need >20% weight loss. For BMI >40, retatrutide's greater efficacy could be the difference between partial and transformative results
- Previous GLP-1 drugs plateaued. If you've tried semaglutide and results have stalled, the triple mechanism may unlock further progress
- You're concerned about metabolic adaptation. The glucagon component may help maintain metabolic rate during weight loss
The Practical Reality
For most Malaysian patients in 2026, semaglutide is the right choice — because it's available, proven, and effective. Starting treatment now with Ozempic or Mounjaro means years of health benefits while retatrutide completes its approval journey.
When retatrutide does arrive, switching will likely be feasible. Your doctor can help you transition if the additional efficacy or metabolic benefits justify it for your situation.
Frequently Asked Questions
Can I switch from Ozempic to retatrutide?
In principle, yes — both are GLP-1-based weekly injectables. The specific switching protocol will be defined during Phase 3 trials and regulatory review. Your doctor will guide the transition, likely involving a dose re-escalation period.
Is retatrutide just a stronger version of Ozempic?
No. While both activate GLP-1 receptors, retatrutide is a fundamentally different drug with two additional mechanisms (GIP and glucagon). It's not simply a higher dose of the same thing — it's a new drug class that works through additional biological pathways.
Will retatrutide replace semaglutide entirely?
Unlikely. Semaglutide will remain relevant for patients who respond well to GLP-1 monotherapy, those who prioritise proven cardiovascular data, budget-conscious patients, and the many people for whom ~15% weight loss is sufficient. The market will likely segment by patient need and price sensitivity.
Are there any head-to-head trials comparing them?
Not yet. The Phase 2 retatrutide trial used a placebo control, not an active comparator. It's possible that Eli Lilly or independent researchers may conduct head-to-head studies in the future, but none are currently registered.
What about oral alternatives?
Eli Lilly is also developing orforglipron, an oral GLP-1 agonist (a daily pill). Novo Nordisk has oral semaglutide (Rybelsus) already available. For patients who dislike injections, oral options will expand significantly by 2028–2030.
The Bottom Line
Retatrutide is poised to be the most effective weight loss medication ever developed — its triple-agonist mechanism produces roughly 60% more weight loss than semaglutide in clinical trials, with additional benefits for liver health and metabolic rate that semaglutide cannot match.
But semaglutide is here now. It's proven, accessible, and producing transformative results for thousands of Malaysians. Waiting 3–4 years for a marginally better drug while living with untreated obesity is rarely the right medical decision.
The best approach for most patients: start treatment today with Ozempic or Mounjaro, build healthy habits, and be ready to upgrade to retatrutide when it reaches Malaysian pharmacies in 2029–2030.
For more detailed information on each drug individually, explore our guides to retatrutide in Malaysia, Ozempic in Malaysia, and Mounjaro in Malaysia.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any treatment, supplement regimen, or making changes to your health routine. Individual results may vary, and what works for others may not work for you.